Emapalumab-lzsg
Emapalumab-lzsg
Emapalumab-lzsg (pronunciation: em-uh-PAL-yoo-mab) is a monoclonal antibody used for the treatment of primary hemophagocytic lymphohistiocytosis (HLH). It is marketed under the brand name Gamifant.
Etymology
The name Emapalumab-lzsg is derived from the International Nonproprietary Names (INN) system. The prefix "Ema-" is arbitrary, "palumab" indicates that it is a monoclonal antibody, and "lzsg" is a suffix used by the United States Adopted Names (USAN) Council to denote substances that have been humanized.
Usage
Emapalumab-lzsg is used to treat primary hemophagocytic lymphohistiocytosis (HLH), a rare and life-threatening condition that affects the immune system. It is used in patients who have failed to respond to conventional treatment or when conventional treatment is not an option.
Mechanism of Action
Emapalumab-lzsg works by binding to and neutralizing interferon gamma (IFNγ), a cytokine that plays a key role in the pathogenesis of HLH. By blocking the action of IFNγ, emapalumab-lzsg helps to reduce the hyperinflammation associated with HLH.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Hemophagocytic lymphohistiocytosis: A severe systemic inflammatory syndrome that can be fatal. It is caused by excessive immune activation.
- Interferon gamma: A type of interferon that is critical for innate and adaptive immunity against viral and intracellular bacterial infections and for tumor control.
External links
- Medical encyclopedia article on Emapalumab-lzsg
- Wikipedia's article - Emapalumab-lzsg
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski